EGFR and neoplasm: This aberrant activity is driven by various oncogenic pathways and dysfunctions in tumor suppressors, including mutated or amplified EGFR, PI3K, Akt, Ras, and Raf, as well as impaired PTEN, APC, LKB1/STK11, and Gator1 [45].